Kefir protective effects against nicotine cessation-induced anxiety and cognition impairments in rats

Noori, Negin; Bangash, Mohammad Yasan; Motaghinejad, Majid; Hosseini, Pantea; Noudoost, Behshad

Kefir protective effects against nicotine cessation-induced anxiety and cognition impairments in rats

Authors

¹ Department of Food Hygiene, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran

² Department of Pharmacology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

Abstract

Background: Nicotine as one of the potent psychostimulant drugs is characterized by its parasympathomimetic activity. Upon the abrupt discontinuation of nicotine intake, a number of symptoms such as anxiety, depression and cognition impairment develop. Kefir as a food supplement is rich in tryptophan. In this study, we have evaluated the effects of Kefir on nicotine cessation-induced anxiety, depression and cognition impairment.
Materials and Methods: Forty adult male rats were divided into four groups. All the groups received 6 mg/kg/day of nicotine for 17 days and then the negative control groups got 5 mg/kg/day of normal saline. The positive control groups were given 40 mg/kg/day of Sertraline HCl for 7 days. The group treated with Cow Milk Kefir (CMK) and Soy Milk Kefir (SMK) received 5 mg/kg/day for 7 days. On the 25 ^th day, Elevated Plus Maze (EPM), Open Field Test (OFT) and Forced Swim Test (FST) were used to investigate anxiety and depression. In addition, Moris Water Maze was applied to evaluate learning and memory in the animals between the 20 ^th and 25 ^th days.
Results: The results showed that administration of CMK, SMK and Sertraline had higher anti-depression and anxiolytic effects on nicotine withdrawal-induced depression and anxiety in rats (P < 0.05). Moreover, CMK and SMK improved learning and memory impairment results in the nicotine withdrawal period (P < 0.05).
Conclusion: This study revealed that Kefir had a potential effect on the treatment of nicotine cessation-induced depression, anxiety and cognition impairment in the animal model. Kefir may be useful for adjunct therapy for nicotine abandonment treatment protocols.

Keywords

References

1.	Mansvelder HD, McGehee DS. Cellular and synaptic mechanisms of nicotine addiction. J Neurobiol 2002;53:606-17.
2.	Dani JA, Ji D, Zhou FM. Synaptic plasticity and nicotine addiction. Neuron 2001;31:349-52.
3.	Picciotto MR, Brunzell DH, Caldarone BJ. Effect of nicotine and nicotinic receptors on anxiety and depression. Neuroreport 2002;13:1097-106.
4.	Kenny PJ, Markou A. Nicotine self-administration acutely activates brain reward systems and induces a long-lasting increase in reward sensitivity. Neuropsychopharmacology 2006;31:1203-11.
5.	Staley JK, Krishnan-Sarin S, Zoghbi S, Tamagnan G, Fujita M, Seibyl JP, et al. Sex differences in [123I]beta-CIT SPECT measures of dopamine and serotonin transporter availability in healthy smokers and nonsmokers. Synapse 2001;41:275-84.
6.	Rao TS, Correa LD, Adams P, Santori EM, Sacaan AI. Pharmacological characterization of dopamine, norepinephrine and serotonin release in the rat prefrontal cortex by neuronal nicotinic acetylcholine receptor agonists. Brain Res 2003;990:203-8.
7.	Chae Y, Yeom M, Han JH, Park HJ, Hahm DH, Shim I, et al. Effect of acupuncture on anxiety-like behavior during nicotine withdrawal and relevant mechanisms. Neurosci Lett 2008;430:98-102.
8.	Kenny PJ, Markou A. Neurobiology of the nicotine withdrawal syndrome. Pharmacol Biochem Behav 2001;70:531-49.
9.	Benowitz NL. Neurobiology of nicotine addiction: Implications for smoking cessation treatment. Am J Med 2008;121(4 Suppl 1):S3-10.
10.	George TP, O'Malley SS. Current pharmacological treatments for nicotine dependence. Trends Pharmacol Sci 2004;25:42-8.
11.	Olausson P, Engel JA, Söderpalm B. Involvement of serotonin in nicotine dependence: Processes relevant to positive and negative regulation of drug intake. Pharmacol Biochem Behav 2002;71:757-71.
12.	Sacco KA, Termine A, Seyal A, Dudas MM, Vessicchio JC, Krishnan-Sarin S, et al. Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: Involvement of nicotinic receptor mechanisms. Arch Gen Psychiatry 2005;62:649-59.
13.	Garrote GL, Abraham AG, De Antoni GL. Chemical and microbiological characterisation of kefir grains. J Dairy Res 2001;68:639-52.
14.	Otles S, Cagindi Oe. Kefir: A probiotic dairy-composition, nutritional and therapeutic aspects. Pak J Nutr 2003;2:54-9.
15.	Eby GA, Eby KL. Rapid recovery from major depression using magnesium treatment. Med Hypotheses 2006;67:362-70.
16.	Kubow S, Fotouhinia M. Kefir as a potent anti-oxidant composition. US Patent 20,040,028,696; 2004.
17.	Singer S, Rossi S, Verzosa S, Hashim A, Lonow R, Cooper T, et al. Nicotine-induced changes in neurotransmitter levels in brain areas associated with cognitive function. Neurochem Res 2004;29:1779-92.
18.	Cary DD. Nicotine addiction treatment. Google Patents; 2001.
19.	Harrison AA, Liem YT, Markou A. Fluoxetine combined with a serotonin-1A receptor antagonist reversed reward deficits observed during nicotine and amphetamine withdrawal in rats. Neuropsychopharmacology 2001;25:55-71.
20.	Morissette SB, Tull MT, Gulliver SB, Kamholz BW, Zimering RT. Anxiety, anxiety disorders, tobacco use, and nicotine: A critical review of interrelationships. Psychol Bulletin 2007;133:245-72.
21.	Prut L, Belzung C. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: A review. Eur J Pharmacol 2003;463:3-33.
22.	Carobrez A, Bertoglio L. Ethological and temporal analyses of anxiety-like behavior: The elevated plus-maze model 20 years on. Neurosci Biobehav Rev 2005;29:1193-205.
23.	Gould TD, Einat H, Bhat R, Manji HK. AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int J Neuropsychopharmacol 2004;7:387-90.
24.	D'Hooge R, De Deyn PP. Applications of the Morris water maze in the study of learning and memory. Brain Res Brain Res Rev 2001;36:60-90.
25.	Tomkins DM, Sellers EM. Addiction and the brain: The role of neurotransmitters in the cause and treatment of drug dependence. CMAJ 2001;164:817-21.
26.	Neumeister A. Tryptophan depletion, serotonin, and depression: Where do we stand? Psychopharmacol Bull 2002;37:99-115.
27.	Lacasse JR, Leo J. Serotonin and depression: A disconnect between the advertisements and the scientific literature. PLoS Med 2005;2:e392.
28.	Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, et al. Antidepressant drug effects and depression severity: A patient-level meta-analysis. JAMA 2010;303:47-53.
29.	Sachs GS, Nierenberg AA, Calabrese JR, Marangell LB, Wisniewski SR, Gyulai L, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 2007;356:1711-22.
30.	Alberghina D, Giannetto C, Visser EK, Ellis AD. Effect of diet on plasma tryptophan and serotonin in trained mares and geldings. Vet Rec 2010;166:133-6.
31.	Meltzer HY, Horiguchi M, Massey BW. The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment. Psychopharmacology (Berl) 2011;213:289-305.
32.	Fukami H, Tachimoto H, Kishi M, Kaga T, Tanaka Y. Acetic acid bacterial lipids improve cognitive function in dementia model rats. J Agric Food Chem 2010;58:4084-9.
33.	Holub I, Kozianowski G. Isomaltulose for use in enhancing mental performance. Google Patents; 2011.
34.	Shaw KA, Turner J, Del Mar C. Tryptophan and 5-hydroxytryptophan for depression. Cochrane Database Syst Rev 2002;1.
35.	Rodrigues KL, Caputo LR, Carvalho JC, Evangelista J, Schneedorf JM. Antimicrobial and healing activity of kefir and kefiran extract. Int J Antimicrob Agents 2005;25:404-8.
36.	Moreira ME, Dos Santos MH, Zolini GP, Wouters AT, Carvalho JC, Schneedorf JM. Anti-inflammatory and cicatrizing activities of a carbohydrate fraction isolated from sugary kefir. J Med Food 2008;11:356-61.
37.	Doðan M. Rheological behaviour and physicochemical properties of kefir with honey. Journal für Verbraucherschutz und Lebensmittelsicherheit 2011;6:327-32.
38.	Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 2002;71:533-54.
39.	Hasselbalch SG, Madsen K, Svarer C, Pinborg LH, Holm S, Paulson OB, et al. Reduced 5-HT2A receptor binding in patients with mild cognitive impairment. Neurobiol Aging 2008;29:1830-8.
40.	Harvey JA. Role of the serotonin 5-HT(2A) receptor in learning. Learn Mem 2003;10:355-62.
41.	Haider S, Khaliq S, Haleem DJ. Enhanced serotonergic neurotransmission in the hippocampus following tryptophan administration improves learning acquisition and memory consolidation in rats. Pharmacol Rep 2007;59:53-7.
42.	Brezun JM, Daszuta A. Depletion in serotonin decreases neurogenesis in the dentate gyrus and the subventricular zone of adult rats. Neuroscience 1999;89:999-1002.
43.	Lauder JM, Krebs H. Serotonin as a differentiation signal in early neurogenesis. Dev Neurosci 1978;1:15-30.
44.	Asemi Z, Jazayeri S, Najafi M, Samimi M, Mofid V, Shidfar F, et al. Effect of daily consumption of probiotic yogurt on oxidative stress in pregnant women: A randomized controlled clinical trial. Ann Nutr Metab 2012;60:62-8.
45.	Ghoneum M, Gimzewski J. Apoptotic effect of a novel kefir product, PFT, on multidrug-resistant myeloid leukemia cells via a hole-piercing mechanism. Int J Oncol 2014;44:830-7.

Advanced Biomedical Research